LGND - Looking For Entry After Apricus And Seelos 'SEEL' The Deal
Seelos Therapeutics was a privately held biopharmaceutical company that recently finalized a reverse merger with Apricus Biosciences "APRI". This merger now allows Seelos to become a public traded company without going through the hassle of an IPO. The combined company is now trading under the ticker SEEL, and will focus on developing the Seelos pipeline candidates for CNS disorders.
Stockholders from the privately owned Seelos now own roughly 85%, while Apricus stockholders own roughly 15% of the merged company. Seelos holders will receive a larger percentage of the company. However, Apricus stockholders will receive